Association of IFNAR2 and TYK2 with COVID-19 pathology: current and future.
作者信息
Razavi Alireza, Raei Maedeh, Shirato Ken
机构信息
Student Research Committee, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Research Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran.
出版信息
Front Immunol. 2024 Sep 16;15:1462628. doi: 10.3389/fimmu.2024.1462628. eCollection 2024.
Abstract
摘要
相似文献
1
Association of IFNAR2 and TYK2 with COVID-19 pathology: current and future.IFNAR2和TYK2与新冠病毒疾病病理学的关联：现状与未来
Front Immunol. 2024 Sep 16;15:1462628. doi: 10.3389/fimmu.2024.1462628. eCollection 2024.
2
Evaluation of IFNAR2 and TYK2 transcripts' prognostic role in COVID-19 patients: a retrospective study.评估 IFNAR2 和 TYK2 转录本在 COVID-19 患者中的预后作用：一项回顾性研究。
Front Cell Infect Microbiol. 2024 Apr 29;14:1356542. doi: 10.3389/fcimb.2024.1356542. eCollection 2024.
3
Expression analysis of IFNAR1 and TYK2 transcripts in COVID-19 patients.COVID-19 患者中 IFNAR1 和 TYK2 转录本的表达分析。
Cytokine. 2022 May;153:155849. doi: 10.1016/j.cyto.2022.155849. Epub 2022 Mar 4.
4
TYK2, IFITM3, IFNAR2 and OAS3 single-nucleotide polymorphisms among severe COVID-19 ICU patients in Morocco.摩洛哥重症 COVID-19 ICU 患者中 TYK2、IFITM3、IFNAR2 和 OAS3 单核苷酸多态性。
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241257241. doi: 10.1177/03946320241257241.
5
Polymorphisms in , , , , and Genes Are Associated with Worse Clinical Outcomes in COVID-19.基因、、、和中的多态性与 COVID-19 的临床结局恶化相关。
Genes (Basel). 2022 Dec 22;14(1):29. doi: 10.3390/genes14010029.
6
Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2.细胞因子信号转导抑制因子（SOCS）1 通过干扰素 α 受体（IFNAR1）相关的酪氨酸激酶 Tyk2 抑制 I 型干扰素（IFN）信号转导。
J Biol Chem. 2011 Sep 30;286(39):33811-8. doi: 10.1074/jbc.M111.270207. Epub 2011 Jul 13.
7
Type I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.I 型干扰素受体在核内控制激活的 TYK2：对 EAE 治疗的影响。
J Neuroimmunol. 2013 Jan 15;254(1-2):101-9. doi: 10.1016/j.jneuroim.2012.10.006. Epub 2012 Oct 27.
8
Basal ubiquitin-independent internalization of interferon alpha receptor is prevented by Tyk2-mediated masking of a linear endocytic motif.酪氨酸激酶2（Tyk2）介导的线性内吞基序的掩盖可防止干扰素α受体的基础泛素非依赖性内化。
J Biol Chem. 2008 Jul 4;283(27):18566-72. doi: 10.1074/jbc.M800991200. Epub 2008 May 12.
9
Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.Janus 激酶信号作为严重 SARS-CoV-2 感染的风险因素和治疗靶点。
Eur J Immunol. 2021 May;51(5):1071-1075. doi: 10.1002/eji.202149173. Epub 2021 Mar 22.
10
Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.木樨草素通过蛋白激酶 A 介导的蛋白酪氨酸磷酸酶 SHP-2 抑制作用激活 Janus 激酶/信号转导和转录激活因子通路信号，从而增强干扰素 α/β 的抗肿瘤增殖作用。
Cell Signal. 2014 Mar;26(3):619-28. doi: 10.1016/j.cellsig.2013.11.039. Epub 2013 Dec 12.
本文引用的文献
1
TYK2, IFITM3, IFNAR2 and OAS3 single-nucleotide polymorphisms among severe COVID-19 ICU patients in Morocco.摩洛哥重症 COVID-19 ICU 患者中 TYK2、IFITM3、IFNAR2 和 OAS3 单核苷酸多态性。
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241257241. doi: 10.1177/03946320241257241.
2
Evaluation of IFNAR2 and TYK2 transcripts' prognostic role in COVID-19 patients: a retrospective study.评估 IFNAR2 和 TYK2 转录本在 COVID-19 患者中的预后作用：一项回顾性研究。
Front Cell Infect Microbiol. 2024 Apr 29;14:1356542. doi: 10.3389/fcimb.2024.1356542. eCollection 2024.
3
Type I interferon pathway genetic variants in severe COVID-19.严重 COVID-19 中 I 型干扰素通路遗传变异。
Virus Res. 2024 Apr;342:199339. doi: 10.1016/j.virusres.2024.199339. Epub 2024 Feb 22.
4
Participation of Single-Nucleotide Variants in and in the Immune Response against SARS-CoV-2 Infection: A Systematic Review.单核苷酸变异在针对严重急性呼吸综合征冠状病毒2感染的免疫反应中的参与：一项系统综述。
Pathogens. 2023 Nov 6;12(11):1320. doi: 10.3390/pathogens12111320.
5
A comprehensive review of ACE2, ACE1, TMPRSS2 and IFITM3 gene polymorphisms and their effect on the severity of COVID-19.ACE2、ACE1、TMPRSS2 和 IFITM3 基因多态性及其对 COVID-19 严重程度影响的综合综述。
Adv Med Sci. 2023 Sep;68(2):450-463. doi: 10.1016/j.advms.2023.10.010. Epub 2023 Nov 3.
6
Association of rs2236757 and rs10735079 Polymorphisms with Susceptibility to COVID-19 Infection and Severity in Palestine.巴勒斯坦地区rs2236757和rs10735079基因多态性与COVID-19感染易感性及严重程度的关联
Interdiscip Perspect Infect Dis. 2023 Sep 16;2023:9551163. doi: 10.1155/2023/9551163. eCollection 2023.
7
Understanding the pivotal roles of ACE2 in SARS-CoV-2 infection: from structure/function to therapeutic implication.了解血管紧张素转换酶2（ACE2）在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染中的关键作用：从结构/功能到治疗意义。
Egypt J Med Hum Genet. 2022;23(1):103. doi: 10.1186/s43042-022-00314-9. Epub 2022 Jun 19.
8
Enhanced inhibition of MHC-I expression by SARS-CoV-2 Omicron subvariants.奥密克戎亚变体增强了对 MHC-I 表达的抑制。
Proc Natl Acad Sci U S A. 2023 Apr 18;120(16):e2221652120. doi: 10.1073/pnas.2221652120. Epub 2023 Apr 10.
9
Association of IFNAR1 and IFNAR2 with COVID-19 severity.IFNAR1和IFNAR2与新冠病毒疾病严重程度的关联。
Lancet Microbe. 2023 Jul;4(7):e487. doi: 10.1016/S2666-5247(23)00095-2. Epub 2023 Apr 4.
10
TYK2 single-nucleotide variants associated with the severity of COVID-19 disease.与 COVID-19 疾病严重程度相关的 TYK2 单核苷酸变异。
Arch Virol. 2023 Mar 23;168(4):119. doi: 10.1007/s00705-023-05729-2.
Zotero 插件